FL-KINAXIS
18.6.2024 17:01:27 CEST | Business Wire | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today introduced the Kinaxis Maestro™ platform, the only AI-infused supply chain orchestration platform with a powerful combination of proprietary computational technologies and techniques that provides full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. An evolution of the company’s flagship platform, RapidResponse, Maestro incorporates new, modern AI technologies to help teams move faster and smarter to master the complexities of today’s modern supply chains.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240618998841/en/
Kinaxis announced its AI-infused orchestration platform, Maestro, at global supply chain conference Kinexions in Miami, FL. (Graphic: Business Wire)
The Maestro platform comprises three layers: a supply chain data fabric connecting internal and external data sources into a single source of truth, an always-on intelligence engine that delivers real-time insights, predictions and adaptive solutions, and a seamless user interface, enabling business leaders to make faster and more valuable decisions than ever before, from anywhere and from any device. For example, in response to skyrocketing demand of a new EV following a high-profile celebrity endorsement, an automaker concerned about component shortages might ask ‘How do I prevent a stockout?’. Without missing a beat, Maestro’s generative AI-powered intelligent assistant will provide guidance based on supply chain best practices to ensure disruptions are absorbed and managed in real-time.
"It’s a challenging time to be a business leader in supply chain. Managing the complexities of global and regional supply chains, balancing agility, cost reduction, and sustainability, and handling a steady stream of geopolitical, economic, and environmental disruptions amid a data explosion,” said Andrew Bell, chief product officer at Kinaxis. “Yet, with the right technologies, there's unprecedented potential to resolve this complexity and master uncertainty. Maestro provides total supply chain transparency, aligns advanced technology with specific challenges, and integrates diverse data—from social media sentiment to government regulations—bringing clarity to chaos so business leaders can sleep soundly at night."
National Instruments took part in the beta phase of Maestro’s generative AI capabilities and Ed Scott, chief program manager said, “From the moment our team deployed Maestro’s intelligent assistant, it was clear it would be a gamechanger. We’ve been able to significantly cut down on the amount of time it takes for users to maximize the value of the platform and we are eager to build on these initial successes as Kinaxis continues to roll out the full breadth of its AI capabilities.”
What makes Maestro different:
- Seamless synchronization. Unmatched agility – Gain a comprehensive, always-on digital view of your supply chain, ensuring continuous synchronization of data, people, and processes for unmatched agility.
- Be ready. Whatever happens – Predict future scenarios with smart modeling and make informed decisions quickly to confidently navigate uncertainties and drive success.
- Strike the perfect balance of accuracy, efficiency, and speed – Fuse machine learning, heuristics and optimization for unparalleled problem-solving, keeping your supply chain at the cutting edge.
- Take your productivity to the next level – Automate routine tasks with AI and predictive algorithms, allowing you to focus on strategic priorities and boost productivity.
- Empower your people to do more with more – Empower your teams with an intuitive tool that simplifies complex tasks and enhances efficiency, enabling greater satisfaction and achievement.
- No data wrangling required – Achieve faster time-to-value by easily ingesting data from various sources without the need for schema definition; just drag, drop, and go.
Global market intelligence firm IDC previewed Maestro prior to launch and Eric Thompson, IDC Worldwide Supply Chain Planning Research Director, noted, “IDC has been discussing end-to-end supply chain integration, and Kinaxis is making moves forward with Maestro. The platform’s progress in combining end-to-end concurrency with smart, user-friendly AI, is a promising step in supply chain orchestration.”
From building the first in-memory material requirements planning (MRP) engine in the 1980s to adopting a SaaS model years before its peers and launching the first cloud-friendly planning platform in the 2000s, Kinaxis has been at the forefront of every major technological innovation within the supply chain industry for the past four decades. The company has consistently prioritized designing products to meet the evolving needs of its customers, focusing on pillars of connectivity, intelligence, adaptability, and user-friendliness. In the previous five years alone, the company’s patent portfolio has grown by more than 500%, with over half of those patents awarded for AI and ML-based innovations.
Celebrating its 40th anniversary in 2024, Kinaxis helps companies that supply the agricultural industry with 40% of the world’s tractors, that keep more than 110 billion teeth clean each year, and that ensure more than 35 million pets are fed nutritious meals each year.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to manage their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618998841/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
